Navigation Links
Micell Technologies Announces Issuance of Core Technology Patent
Date:11/6/2012

DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES™), as well as potential additional biomedical products. The patent rights are assigned to and wholly owned by Micell.

The patent, "Polymer Coatings Containing Drug Powder of Controlled Morphology" (US Patent Number 8,298,565), covers:

  • Coating methods enabling medical devices with unique and potentially advantageous clinical properties.
  • Coating methods that are key to Micell's proprietary manufacturing technology.  
  • Formulations for implantable device/drug combination products, which are intended to confer enhanced stability and delivery by controlling the morphology of the drug(s) in the coating.

James B. McClain, Ph.D., Senior Vice President and co-founder of Micell, said, "This marks an important milestone in the execution of Micell's international intellectual property strategy. This patent issuance is the beginning of the realization of over 6,000 filed patent claims and supports our belief that Micell's coating technology and methods are novel, differentiated, scalable and transferable."

Micell currently is using its proprietary technology in products under development including the MiStent SES -- a thin-strut sirolimus-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release.  The MiStent SES clinical development program recently completed the 12-month patient follow-up in the DESSOLVE II study and 18 month patient follow-up in the DESSOLVE I study.  In addition, Micell also has a drug-coated
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
2. Life Technologies Acquires Advanced Microscopy Group
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
4. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
5. Life Technologies Collaborates with USDA to Develop Same-Day, Multi-Strain E. coli Detection System
6. LightPath Technologies Provides Quarterly Update on Infrared Initiatives
7. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
8. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
9. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
10. Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections
11. DiFUSION Technologies Announces Breakthrough Medical Polymer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)...  According to the American Optometric Association (AOA), parents ... devices. An AOA survey reports that 83 percent of ... they use an electronic device for three or more ... parents revealed that only 40 percent of parents believe ... amount of time. Eye doctors are concerned that this ...
(Date:7/22/2014)... MARCOS, Texas , July 22, 2014 Quantum Materials ... and Mr. John Heaton to the Board of ... by Dr. Ghassan Jabbour , QMC Chief Science Officer and ... Michael Wong of Rice University and Mr. Tomio ... Japan . " Quantum Materials welcomes ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Pharmaceuticals, Inc. announced today that the U.S. Food ... drug status for the treatment of pancreatic cancer. ... the marketed chemotherapy drug irinotecan.  MM-398 is partnered ... Taiwan under the designation PEP02. (Logo: ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... the NASDAQ Global Select Market closes on Tuesday, August 9, ... Executive Officer, will host a conference call and webcast at ... the financial results for the second quarter 2011 and to ...
Cached Medicine Technology:FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 3
(Date:7/22/2014)... 2014 Air Conditioning & Heating Inc. ... authorized Daikin comfort pro dealer. This means that the ... and cooling system equipment. Only a select few businesses ... before being approved. , Daikin co-developed an R-410A refrigerant ... System Air Conditioning Market. They are also the inventor ...
(Date:7/22/2014)... July 22, 2014 Dr. Dental is excited ... patients and new visitors in mind, one of the main ... visual layout that makes navigation very easy. Dr. Dental is ... of going to the dentist affordable, convenient and fun, and ... new feature is an appointment scheduling system right on the ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 Dr. ... with his surgical colleagues, have recently discussed the reasons ... Many leaders in the periodontics profession are seeing the ... go up exponentially. In fact, one surgeon reported that ... failing implants. Although dental implants have a very high ...
(Date:7/22/2014)... The 2014 Warrior-Family Symposium (WFS) ... Building and International Trade Center in Washington, D.C. ... Civilian Communities,” will be held from 8:30 a.m. ... and cohosted by the Military Officers Association of ... (NDIA). USAA is the Executive Sponsor of the ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's leading ... an insurance veteran with more than 15 years of ... based in the company's Chicago office. , UBA Board ... chose to accept this important, strategic position with UBA. ... challenges facing UBA and its Partners as we move ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Dr. Dental Reveals Exciting New Website 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5
... as soon as possible, researchers say , MONDAY, May ... breast lesions found in women with a high risk ... suggest. , An indeterminate breast lesion is one that ... women include those who have breast cancer, a history ...
... urged to consider risks of hormone treatment, inform patients ... widely used class of prostate cancer drugs called gonadotropin-releasing ... attack, stroke and sudden death in men, a U.S. ... on initial findings from a preliminary and ongoing analysis ...
... While timely care can reduce stress among breast cancer ... compromise other factors important to care, such as safety, effectiveness, ... the April issue of the Journal of the American ... cancer diagnosis and one in eight women will receive ...
... States will have an osteoporosis-related fracture in her lifetime (1). ... 2010 issue of the Journal of the American Academy ... women will be tested and treated for osteoporosis, which if ... fractures. "Less than 10 percent of patients who sustain ...
... ... Medical Group, a Torrance, California-based healthcare organization, today announced the acquisition of Talbert ... managed care patients in Los Angeles County and Orange County, California. , ... Torrance, CA ...
... key, study finds , MONDAY, May 3 (HealthDay News) ... their children from becoming bullies by helping them with ... study suggests. , "Improving parent-child communication and parental ... on child bullying," said study author Dr. Rashmi Shetgiri, ...
Cached Medicine News:Health News:Aggressive Action Urged When Evaluating Breast Lesions 2Health News:FDA Reviews Side Effects From Prostate Cancer Therapy 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 3Health News:Women want answers, but what questions should be asked? 2Health News:Women want answers, but what questions should be asked? 3Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 2Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 3Health News:Involved Parents Less Likely to Raise Bullies 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... kit measures the biologically active form ... is a valuable prognostic marker for cardiovascular ... plasma vitamin B6 level and Coronary Heart ... reactions of homocysteine to cystathionine and then ...
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: